Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study
Background: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments. Methods: A retrospective cohort study was done to evaluate the effectivenes...
Main Authors: | Andac Salman, Tulin Ergun, Ana Maria Gimenez-Arnau |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-02-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2019.1589639 |
Similar Items
-
Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01) -
Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
by: Rabia Kara, et al.
Published: (2022-09-01) -
Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01) -
Omalizumab's efficacy and safety against chronic spontaneous urticaria
by: Öner Özdemir
Published: (2023-08-01) -
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
by: Anthony F. LaCava, et al.
Published: (2023-08-01)